In-licensing is an important mechanism by which NMI is building a diversified product pipeline. We continue to search for and evaluate highly specific / targeted therapeutic opportunities which may complement our existing pipeline. In addition to compounds with attractive intrinsic properties, NMI is particularly interested in candidate therapies for which the application of our molecularly targeted technology platform could offer the potential to derive unique insights into patient selection that may help inform clinical development and create differentiation from competitors.
We also remain committed to accessing the best technologies and tools to support our research and development efforts through collaborations and licenses. To supplement our own molecular targeted technology and capabilities, NMI has entered into various collaborations agreements in order to access advanced tools for drug discovery.